Tempest Therapeutics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $7.20 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Tempest Therapeutics Inc had its IPO on 2012-11-12 under the ticker symbol TPST.
The company operates in the Healthcare sector and Biotechnology industry. Tempest Therapeutics Inc has a staff strength of 19 employees.
Shares of Tempest Therapeutics Inc opened at $0.44 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.44 - $0.58, and closed at $0.57.
This is a +30.14% increase from the previous day's closing price.
A total volume of 504,466 shares were traded at the close of the day’s session.
In the last one week, shares of Tempest Therapeutics Inc have increased by +5.56%.
Tempest Therapeutics Inc's Key Ratios
Tempest Therapeutics Inc has a market cap of $7.20 million, indicating a price to book ratio of 0.6148 and a price to sales ratio of 0.
In the last 12-months Tempest Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-32130000. The EBITDA ratio measures Tempest Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Tempest Therapeutics Inc’s operating margin was 0% while its return on assets stood at -40.11% with a return of equity of -166.57%.
In Q2, Tempest Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Tempest Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-2.16 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Tempest Therapeutics Inc’s profitability.
Tempest Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.2975. Its price to sales ratio in the trailing 12-months stood at 0.
Tempest Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $30.74 million
- Total Liabilities
- $8.64 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Tempest Therapeutics Inc ended 2023 with $30.74 million in total assets and $0 in total liabilities. Its intangible assets were valued at $30.74 million while shareholder equity stood at $5.01 million.
Tempest Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $8.64 million in other current liabilities, 13000.00 in common stock, $-150989000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $17.60 million and cash and short-term investments were $17.60 million. The company’s total short-term debt was $4,388,000 while long-term debt stood at $7.48 million.
Tempest Therapeutics Inc’s total current assets stands at $18.54 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $868000.00 and inventory worth $0.
In 2023, Tempest Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $117000.
Comparatively, Tempest Therapeutics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Tempest Therapeutics Inc stock is currently trading at $0.57 per share. It touched a 52-week high of $4.214 and a 52-week low of $4.214. Analysts tracking the stock have a 12-month average target price of $15.67.
Its 50-day moving average was $0.82 and 200-day moving average was $1.52 The short ratio stood at 0.1 indicating a short percent outstanding of 0%.
Around 300% of the company’s stock are held by insiders while 6891.7% are held by institutions.
Frequently Asked Questions About Tempest Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company’s two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.